US FDA clears Roche's Elecsys® pTau217 blood test, developed in collaboration with Lilly, to aid identification of amyloid pathology associated with Alzheimer's disease
The US Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test¹, developed by Roche in collaboration with Eli Lilly and Company, to aid in identifying amyloid pathology associated with Alzheimer's disease.
The test provides clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology in individuals aged 55 years and older with signs, symptoms, or complaints of cognitive decline. Elecsys® pTau217 is the first and only FDA-cleared, single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings.
The clearance comes amid increasing interest in blood-based biomarkers as tools that could make assessment of Alzheimer’s disease pathology more accessible and less invasive.
Traditional approaches used to assess amyloid pathology, including positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, may be costly, invasive, and difficult to access outside specialty centres.
Blood Test May Help Address Barriers to Alzheimer’s Disease Assessment
The Elecsys® pTau217 blood test helps address these barriers by providing a minimally invasive blood-based option that can be incorporated into existing clinical and laboratory workflows. The test may help clinicians assess the likelihood of amyloid pathology earlier in the disease and diagnostic pathway and identify patients who should be considered for additional evaluation or specialist referral.
The assay provides positive, intermediate, and negative result categories to support assessment of the likelihood of amyloid pathology. Results are interpreted in conjunction with clinical information and other relevant findings as part of the Alzheimer’s disease diagnostic pathway.
In India, an estimated 7.4% of people aged 60 years and older live with dementia, representing approximately 8.8 million individuals. If this prevalence remains the same, the number of people living with dementia is projected to reach 16.9 million by 2036, driven by the growth of the older Indian population².
Elecsys® pTau217 may help healthcare providers and health systems support clinical decision-making across primary and specialty care, identify appropriate next steps based on the likelihood of amyloid pathology, and facilitate a more efficient diagnostic pathway by offering a minimally invasive blood-based option to help determine when targeted further evaluation, including PET imaging or CSF testing, may be appropriate.
The test’s rule-in and rule-out capabilities using the same clinical cutoffs could also support assessment at different stages of the diagnostic pathway.
Despite the FDA clearance, Elecsys® pTau217 is not intended to be used as a standalone diagnostic test for Alzheimer’s disease. Test results should be interpreted along with clinical information and other relevant diagnostic findings. A result indicating the likelihood of amyloid pathology does not, by itself, establish a diagnosis of Alzheimer’s disease.
The FDA clearance adds to the growing clinical use of blood-based biomarkers in Alzheimer’s disease assessment. For clinicians evaluating older adults presenting with cognitive decline, the availability of a blood-based test that can support both rule-in and rule-out assessment of amyloid pathology could provide an additional practical tool within the evaluation and diagnostic pathway.
References:
1) Roche. Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care [Internet]. Basel (Switzerland): Roche; 2026 Aug 24 [cited 2026 Aug 26]. Available from: https://www.roche.com/investors/updates/inv-update-2026-08-24
2) Lee J, et. al Prevalence of dementia in India: National and state estimates from a nationwide study. Alzheimers Dement. 2023 Jul;19(7):2898-2912. doi: 10.1002/alz.12928. Epub 2023 Jan 13. Erratum in: Alzheimers Dement. 2025 Jul;21(7):e70555. doi: 10.1002/alz.70555. PMID: 36637034; PMCID: PMC10338640.
CMAT-22226 | 27/08/2026
The information provided in this section is intended solely for the use of registered medical practitioner. For further Information about Lilly and Lilly products please contact us at: Atrium Place, 11th Floor, Tower B, Block C, Vanijya Nikunj, Phase V, Udyog Vihar, Sector 19, Gurugram, Haryana 122016. Ph.: +91-124-4753000/01 | www.lilly.com/in. For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com. For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com . This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.
© 2026 Eli Lilly and Company. All Rights Reserved
Eli Lilly Privacy Policy: https://privacynotice.lilly.com/global/
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.